Selenium and Vitamin E for Prostate Cancer: Post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) Status

Ledesma, Mark C.; Jung-Hynes, Brittney; Schmit, Travis L.; Kumar, Raj; Mukhtar, Hasan; Ahmad, Nihal

doi:10.2119/molmed.2010.00136

Cited by 69 publications

(50 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One possible reason for this was that the oral doses or formulations of L-selenomethionine (supplemental selenium used in the trail) have not been fully established and selenium metabolites delivered to islet cells may not enough to cause effects [35].…”

Section: Tablementioning

confidence: 99%

High levels of plasma selenium are associated with metabolic syndrome and elevated fasting plasma glucose in a Chinese population: A case-control study

Yuan

et al. 2015

Journal of Trace Elements in Medicine and Biology

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 99%

High levels of plasma selenium are associated with metabolic syndrome and elevated fasting plasma glucose in a Chinese population: A case-control study

Yuan

et al. 2015

Journal of Trace Elements in Medicine and Biology

View full text Add to dashboard Cite

“…A large body of literature has documented that selenium may modify the risk of several major types of cancer even through many controversies remain [12][13][14][15][16][17][18][19]. The anticancer activity of selenium supplementation mainly depends on its chemical forms and dosages [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad

et al. 2011

View full text Add to dashboard Cite

ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins, holds great promise to complement current cancer therapies. However many types of solid cancer cells are resistant to ABT-737. One practical approach to improve its therapeutic efficacy is to combine with the agents that can overcome such resistance to restore the sensitivity. In the present study, a second-generation selenium compound methylseleninic acid (MSeA) synergistically sensitized MDA-MB-231 human breast cancer cells, HT-29 human colon cancer cells and DU145 human prostate cancer cells to apoptosis induction by ABT-737, as evidenced by greater than additive enhancement of Annexin V/FITC positive (apoptotic) cells and activation of multiple caspases and PARP cleavage. Mechanistic investigation demonstrated that MSeA significantly decreased basal Mcl-1 expression and ABT-737-induced Mcl-1 expression. Knocking down of Mcl-1 with RNAi approach supported the functional significance of this molecular target. More importantly, we identified inactivation of Bad by phosphorylation on ser-136 and ser-112 as a novel mechanism involved in ABT-737 resistance, which can be overcome by combining with MSeA. In addition, we found that expression of Bax was required for the efficient execution of synergistic sensitization. Our findings, for the first time, provide a strong mechanistic rationale for developing MSeA as a novel sensitizing agent of ABT-737.

show abstract

“…The basis of the SELECT trial was the preclinical animal studies and correlational population studies. The randomized, double-blind, placebo-controlled clinical trial, surprisingly, found that neither selenium nor vitamin E reduced the incidence of prostate cancer and that vitamin E alone was associated with a 17% increased risk of prostate cancer compared to placebo [82][83][84][85][86][87].…”

Section: Lessons From the Select Trialmentioning

confidence: 99%

“…The primary hypothesis-generating trial prompting inclusion of selenium in SELECT was the randomized double blind Nutritional Prevention of Cancer (NPC) Trial with 1312 American participants who had a history of skin cancer. Another trial, the ATBC (α-Tocopherol/β-carotene) trial gave the inspiration for inclusion of vitamin E in the SELECT trial [82][83][84][85][86][87]90].…”

Section: Lessons From the Select Trialmentioning

confidence: 99%

Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science

Zhang¹,

Nag²

2014

Pharma-Nutrition

View full text Add to dashboard Cite

Selenium and Vitamin E for Prostate Cancer: Post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) Status

Cited by 69 publications

References 110 publications

High levels of plasma selenium are associated with metabolic syndrome and elevated fasting plasma glucose in a Chinese population: A case-control study

High levels of plasma selenium are associated with metabolic syndrome and elevated fasting plasma glucose in a Chinese population: A case-control study

Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad

Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science

Contact Info

Product

Resources

About